animal model for human mesial temporal lobe epilepsy (mTLE). New and existing molecules could prove useful as lead compounds for the development of therapeutics for neuropathologies that have aberrant glutamatergic signaling as a central component. In this chapter we discuss natural source origins and pharmacological activities of those marine compounds that target ionotropic glutamate receptors.
Introduction
Marine organisms have provided some of the most well-known and widely used ligands for mammalian iGluRs (Fig. 1) . Indeed, one family of iGluRs, the kainate receptors, was named for a molecule derived from a common variety of seaweed that was used extensively in Japanese native medicine as an anthelmintic to treat ascariasis. Despite the prominence in neuroscience research of a limited set of marine natural products that target iGluRs, in sheer numbers far more iGluR-active secondary metabolites, particularly amino acid derivatives, have been derived from terrestrial sources (Moloney 1998 (Moloney , 1999 (Moloney , 2002 . Notable examples include quisqualic acid, from H -Gly -Glu -Gla -Gla -Leu -Gln -Gla -Asn -Gln -Gla -Leu -Ile -Arg -Gla -Lys -Ser -Asn -NH 2
Fig. 1 Chemical structures of representative iGluR ligands discussed in this chapter

